Argenx Files for FDA Approval of Efgartigimod for Generalized MG
Monashee Investment Management LLC Reduces Stock Position in argenx SE (NASDAQ:ARGX) - MarketBeat
Une année faste pour la biotech Argenx et ses anticorps de lamas | Paperjam News
News & warnings | FSMA
Genmab expands immunology reach in argenx pact
Argenx Is Tracking Well Above the Industry
argenx | News
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
Argenx Follows up Phase III Success with Giant €785M Global Offering
ARGENX SE Form 6-K Current Report Filed 2023-01-09
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
argenx Receives the EMA's CHMP Positive Opinion of Efgartigimod for Generalized Myasthenia Gravis
PRESS RELEASE
argenx | News
ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
ARGENX SE Form 6-K Current Report Filed 2023-01-09
Katrina Sergeev Gary, CPXP on LinkedIn: #myastheniagravis #patientsfirst #innovation #cocreation #excellence
ARGENX SE - Together We Discover Reaching Patients Through Immunology Innovation March 22, 2022 Topline Results: ADAPT - SC Bridging Study in gMG 1 - EX-99.2 - March 22, 2022
IQVIA selected to accelerate clinical development of VYVGART by argenx SE | World Pharma Today
Buy argenx Stock - ARGX Stock Price Today & News - Public.com
argenx announces launch of proposed global offering
argenx Announces U.S. Food and Drug Administration Approval
Argenx ARGX Q3 2023 Earnings Call & Presentation - YouTube
REACH Market Research on LinkedIn: argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo…
Myasthenia Gravis Foundation of America, Inc. - argenx announces positive topline results from Phase 3 ADAPT trial for gMG. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia
argenx | News
Raya Therapeutic announces early-stage R&D collaboration with argenx
FDA clears subcutaneous version of argenx's Vyvgart
SEC Filing | argenx
